1. Pink Sheet

India Prevenar 13 Patent Challenge Closely Watched As Test Case

 
• By Penelope MacRae

Ruling could come as early as next month in international humanitarian group MSF’s challenge to Pfizer's application for Indian patent on its blockbuster pneumococcal vaccine; observers see ruling as test of whether India is sticking to its stringent patent policy in face of growing pressure from foreign pharmaceutical companies.

India_moneybox_1200x675

Prevenar 13 has already been denied a patent by the European Patent Office and Médicins sans Frontières (MSF; Doctors Without Borders) is hoping to make it two strikes in a row against Pfizer Inc.’s best-selling vaccine.

Hearings are being held at the Indian Patent Office in capital New Delhi on Pfizer’s patent application and a ruling is

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet